Amyris (NASDAQ:AMRS) Price Target Cut to $5.00 by Analysts at HC Wainwright

Amyris (NASDAQ:AMRS – Get Rating) had its target price dropped by equities researchers at HC Wainwright from $22.00 to $5.00 in a research report issued to clients and investors on Thursday, The Fly reports. HC Wainwright’s price objective would indicate a potential upside of 293.70% from the company’s previous close.

Separately, Piper Sandler dropped their price target on Amyris from $2.50 to $2.00 in a research report on Tuesday, January 3rd. One analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. According to data from MarketBeat.com, Amyris has an average rating of “Hold” and an average price target of $4.63.

Amyris Stock Down 3.8 %

Shares of AMRS opened at $1.27 on Thursday. The business’s 50 day moving average price is $1.45 and its 200-day moving average price is $2.10. Amyris has a 52 week low of $0.99 and a 52 week high of $5.15. The stock has a market cap of $419.30 million, a P/E ratio of -0.72 and a beta of 1.10.

Hedge Funds Weigh In On Amyris

A number of hedge funds have recently added to or reduced their stakes in AMRS. Edmond DE Rothschild Holding S.A. raised its holdings in Amyris by 52.6% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 6,965,700 shares of the biotechnology company’s stock worth $12,887,000 after acquiring an additional 2,401,900 shares during the last quarter. Norges Bank purchased a new position in Amyris in the 4th quarter worth approximately $2,007,000. Credit Suisse AG raised its holdings in Amyris by 43.9% in the 3rd quarter. Credit Suisse AG now owns 3,109,050 shares of the biotechnology company’s stock worth $9,079,000 after acquiring an additional 949,232 shares during the last quarter. EVR Research LP purchased a new position in Amyris in the 3rd quarter worth approximately $2,628,000. Finally, GW&K Investment Management LLC raised its holdings in Amyris by 136.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,258,417 shares of the biotechnology company’s stock worth $1,925,000 after acquiring an additional 726,367 shares during the last quarter. 43.08% of the stock is currently owned by hedge funds and other institutional investors.

About Amyris

(Get Rating)

Amyris, Inc engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.